We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
-
AI and Digital Health
-
Biomanufacturing
-
Brain Health
-
Business Development and Investment
-
Cardiovascular
-
Cell and Gene Therapy and Genome Editing
-
Diagnostics and Personalized Medicine
-
Diversity and Opportunity
-
Emerging Opportunities in Global Markets
-
Environmental Sustainability
-
Immunology
-
Infectious Disease and Vaccines
-
Inflammation
-
Intellectual Property and Legal Landscape
-
Metabolic Diseases
-
Multiline Global Biopharma
-
Next Generation Biotherapeutics
-
Oncology
-
Orphan and Rare Disease
-
Other
-
Pain Management
-
Patient Advocacy
-
Platform for Therapeutics
-
Regenerative Medicine
-
Regulatory Innovation
-
Respiratory
-
Tools/Drug Development Support Tech
-
Translational Research
-
Value‚ Patient Access and Reimbursement
8:30 AM
-
This advanced course is ideal for professionals already in business development & licensing roles, from those with limited experience (2-3 years) to highly experienced dealmakers looking to hone their ...
-
This introductory-level course is designed for professionals new to the life sciences business development field or for individuals with some experience who are interested in updating their profession ...Faculty
.jpg)
.jpg)
8:30 AM
-
This introductory-level course is designed for professionals new to the life sciences business development field or for individuals with some experience who are interested in updating their profession ...Faculty
-
This advanced course is ideal for professionals already in business development & licensing roles, from those with limited experience (2-3 years) to highly experienced dealmakers looking to hone their ...
-
This introductory-level course explains the path to transform a biotechnology invention into a viable start-up company, suited for biotech or MedTech entrepreneurs from the managerial, scientific, and ...Faculty
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.png)
8:30 AM
-
This introductory-level course explains the path to transform a biotechnology invention into a viable start-up company, suited for biotech or MedTech entrepreneurs from the managerial, scientific, and ...Faculty
-
This advanced course is ideal for professionals already in business development & licensing roles, from those with limited experience (2-3 years) to highly experienced dealmakers looking to hone their ...
-
This introductory-level course is designed for professionals new to the life sciences business development field or for individuals with some experience who are interested in updating their profession ...Faculty
9:00 AM
-
This intermediate course explains how to effectively position your company’s story, strategy, and value proposition for institutional investors by maximizing the chances of successfully completing a s ...
-
This intermediate course is for executives and business development professionals interested in enhancing their skills in negotiations, influencing, decision-making, and game theory. Game theory will ...
-
This introductory-level course explains a systematic approach for producing a valuation and risk profile for a company or product to be used in investment rounds, mergers/acquisitions, licensing deals ...
.jpg)
12:00 PM
-
This introductory-level course will equip early-stage biotechnology leaders with the commercialization knowledge they need to strategically position their organizations for financing success and meeti ...Faculty
1:00 AM
-
Biosyngen, a biotechnology company headquartered in Singapore that focuses on unmet therapeutic needs in cancer patients. Biosyngen develops first-in-class immunotherapy-based strategies to provide ca ...Primary Speaker -
Medincell is a commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medica ...Primary Speaker -
Bostal LLC is an enabling platform technology pharmaceutical company. Established in New Jersey in 2004, Bostal expanded its global footprint, Bostal Drug Delivery, in China in 2013. With its long-act ...Primary Speaker -
Canopy is an emerging biotech redefining autoimmune therapeutics through its groundbreaking Antigen-Drug Conjugate (AgDC) platform. Backed by leading US-based VCs, the company is led by Dr. Kfir Oved, ...Primary Speaker -
.jpg)
Founded in 2023, Gifted Molecular Science is committed to developing innovative antiviral therapies with a novel mechanism of action to combat COVID-19. With $4.0M from a strategic investor and $1.5M ...Primary Speaker -
Accelerated Biosciences is a regenerative medicine company commercializing the human Trophoblast Stem Cell (hTSC). hTSCs are the earliest stem cells that can be sourced without ethical issues. The hol ...Primary Speaker -
GenVivo is a private, clinical-stage company with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own ...Primary Speaker -
Hyundai Bioscience is a biotech company in South Korea dedicated to therapeutic solutions for infectious diseases and cancer. We repurpose and expand indications of existing drugs using our novel DDS ...Primary Speaker -
Endourage is developing novel therapeutics for Chronic Disease. The company is preparing to bring its platform of 11 therapeutics, all developed in humans and with human clinical data into the FDA's b ...Primary Speaker -
Cha Therapeutics aims to improve cancer outcomes by combining immune checkpoint inhibitors (ICIs) with its proprietary epigenetics-plus platform. Our first-in-class epigenetic disruptor, CHA1, targets ...Primary Speaker -
RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products ...Primary Speaker -
Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on centr ... -
RNA AI Platform for Next Generation Cures - because by analyzing RNA, we can detect disease, monitor health, and design the Next Generation Cures RNA is the cell software, and by decoding it, we can r ...Primary Speaker -
SLAM Bio is an oncology biotech company developing a platform of first-in-class antibodies and ADCs against signaling lymphocytic activation molecule (SLAM) protein family. This is an intriguing biote ... -
Junevity is a longevity biotechnology company developing Cell Reset therapeutics, a new class of medicines reversing transcriptional damage with siRNA. Junevity’s RESET platform is the first to use la ...Primary Speaker -
Azafaros, founded in 2018, is a clinical-stage company addressing lysosomal storage disorders, including GM1 and GM2 gangliosidoses and Niemann-Pick type C. With roots in discoveries from Leiden Unive ...Primary Speaker -
Zambon Biotech SA is a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, ... -
Dyadic International, Inc., founded in 1979, transitioned from an industrial textiles company to a Nasdaq-listed global biotechnology company focused on microbial platforms for biopharmaceutical and b ... -
Samjin Pharmaceutical Co., Ltd., a leading pharmaceutical company in Korea established in 1968, is dedicated to pioneering advancements in therapeutic innovation. Our portfolio features renowned produ ... -
EG 427 is the worldwide leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, with an Investigational New Drug (IND) application for its lead product cleared by the FDA cleared in ...Primary Speaker -
Antibiotic resistance is one of the greatest challenges in modern medicine, driving the urgent need for alternative treatments. Bacteriophage therapy offers a promising solution by using naturally occ ... -
Speratum Biopharma is pioneering the future of precision oncology with cutting-edge miRNA-based therapeutics. Our lead program, NM-198, leverages our proprietary Nano-In™ and NoPass™ delivery platform ... -
.png)
Creating the ideal immunotherapy which provides potent tumour-selective delivery and tumour-selective killing ability through IV delivery. Lead program entering the clinic in 2025.Primary Speaker -
Founded by serial entrepreneurs and Harvard professors John Iafrate and David Weitz, Hunter BioDiscovery designed an AI-guided, high-throughput platform called FlowMatrixTM to rapidly assess drug syne ...Primary Speaker -
Psy Therapeutics discovers and develops innovative medicines for neuropsychiatric and neurological disorders, including PTSD, depression, Chronic Pain, Alzheimer’s, and Parkinson’s. Our robust pipelin ...Primary Speaker -
Cenyx Biotech Inc. is a pioneering nanomedicine company developing first-in-human cerium oxide-based nanozyme for acute and chronic inflammatory diseases with high unmet needs. Our lead candidate, CX2 ...Primary Speaker -
.png)
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cam ...Primary Speaker -
Osmol is a clinical stage biopharma company advancing technology licensed from Yale to develop a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a ...Primary Speaker -
Ziphius, a Belgium/US-based private biotech company, is advancing a next-generation platform utilizing self-amplifying RNA (saRNA) and lipid nanoparticles (LNPs) to develop first and best in class med ...Primary Speaker -
We are pioneering the development of a completely new class of drugs based on the messenger RNA (mRNA). The basic principle is the use of this molecule as a data carrier for information, with the help ...Primary Speaker -
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide more accessible, effective and sustainable solutions acr ...Primary Speaker -
NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein Nanosyringes as a next-generation platform technolog ...Primary Speaker -
GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and ...Primary Speaker -
.png)
InnoCure Therapeutics is a global biopharmaceutical company dedicated to the discovery and development of novel drugs based on next-generation Target Protein Degradation (TPD) mechanisms applicable to ... -
ImmuneWalk Therapeutics is clinical-Stage company developing therapies for I&I. Our main program is based on the discovery of a novel adhesion checkpoint, that controls the ability of certain immune c ...Primary Speaker -
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detec ... -
Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. Our innovative antibody technologies have led to multiple th ... -
Boehringer Ingelheim is an independent company and a global leader in both animal and human health. We focus on delivering breakthrough innovation - wherever it originates - to tackle the most importa ... -
Yokogawa founded in Tokyo, Japan in 1915, is a global leader in industrial automation and control, test and measurement, information systems, and industrial services. With over a century of innovation ...Primary Speaker -
Avstera Therapeutics is a biotech company based in Malvern, PA developing next gen best-in-class oral selective HDAC6 inhibitors targeting a myriad of diseases including obesity, cancer and other card ...Primary Speaker -
Vasthera Co., Ltd. is a Korea-based pre-clinical stage pharmaceutical company pioneering first-in-class drugs for chronic inflammatory diseases, such as cardiovascular, cancer, eye, and neurodegenerat ...Primary Speaker -
Artiva (NASDAQ: ARTV) is a San Diego-based, clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune dise ... -
At GenEdit, our mission is to develop innovative genetic medicines with targeted in vivo delivery. Our NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs) offer a combination ... -
Chimeric Therapeutics is a clinical stage cell therapy company. CHM has four phase 1 clinical trials across three assets. CHM is proud to be developing two Auto-CAR-Ts, one for GI cancers and another ...Primary Speaker -
Neurizon is a publicly listed Australian company (ASX:NUZ) that is developing NUZ-001 for the treatment of neurodegenerative diseases. NUZ-001 is a small molecule mTOR inhibitor that activates autopha ... -
VRG Therapeutics is a leader in pharma R&D with world-class AI-driven drug discovery platform that combines in silico and wetlab capabilities to create miniproteins with extreme selectivity and outsta ...Primary Speaker -
King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) is a premier institution in the Kingdom of Saudi Arabia specializing in health sciences education and research. Established in collabor ... -
King Abdullah International Medical Research Center (KAIMRC) aims to translate laboratory results into impactful healthcare products while cultivating skilled researchers. As a leading research organi ...Primary Speaker -
BASF Bioservices provides contract Protein Discovery, Engineering, Microbial Strain & Process Development, and Data Services to Life Science and Biotech companies. -
Pin Therapeutics was founded in South Korea in 2018. We are an innovative biotech company developing a targeted protein degradation platform focused on novel E3 ligases (PinE3) and molecular glue degr ...Primary Speaker -
.jpg)
Curapath is a leading CDMO specializing in innovative drug delivery systems (DDS), with expertise in lipid nanoparticles (LNPs) and polymer nanoparticles (PNPs). Offering comprehensive support from de ...Primary Speaker -
pacDNA is a seed-stage company aiming to transform the field of gene regulation therapeutics with our Brushield™ oligonucleotide delivery technology, which addresses several pain points in one simple ...Primary Speaker -
At Oxford BioTherapeutics, our oncology discovery capabilities span a diverse range of modalities, all underpinned by our proprietary target discovery platform OGAP®-Verify that drives our mission to ... -
Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing the ... -
Curocell is a commercial-stage cell therapy company spanning from development to commercial manufacturing. Our mission is to transform cancer treatment by developing innovative, robust, and scalable c ...Primary Speaker -
XtalPi is a pioneering technology company reshaping drug discovery through an integrated platform that leverages AI, automation, and advanced digital tools. The company accelerates the research and de ...Primary Speaker -
Clever Culture Systems (ASX: CC5) is an Australian biotechnology leader developing AI-powered microbiology solutions. Their flagship product, the Automated Plate Assessment System (APAS), addresses a ...Primary Speaker -
BioAro Inc., a Calgary-based Canadian biotechnology leader, is revolutionizing precision medicine through innovative solutions in Point-of-Care (POC) In Vitro Diagnostics (IVD), wearable sensors, and ...Primary Speaker -
Atom Therapeutics is a privately held Chinese clinical stage pharmaceutical company engaged in new drug discovery and development of treatments for inflammatory and metabolic diseases. We have raised ...Primary Speaker
.png)
.jpg)
.jpeg)
.png)
.jpg)
11:00 AM
-
This panel of iconic healthcare and life sciences investors will share their perspectives on top areas for AI and digital health investment. Recent reports show that the number of AI deals in healthca ...Moderator
12:00 PM
-
This session aims to illuminate the cutting-edge technical approaches of AI-driven biologics drug discovery companies. Speakers will explore the ongoing R&D efforts in developing platforms and pipelin ...Speakers
.jpeg)
.jpeg.jpg)
1:45 PM
-
Across therapeutic areas, oncology is richest in depth of pipeline and variety of potential modalities/mechanisms of action. Of nearly 200 different products in Phase 3 alone, small molecules are now ...
-
Since its inception in 1992, the FDA has greenlit nearly 300 new drugs under its accelerated approval pathway, with notable nods in oncology, Alzheimer’s disease, and amyotrophic lateral sclerosis. It ...
-
Artificial intelligence (AI) is already revolutionizing drug discovery and development by accelerating the identification of novel targets, optimizing molecules, and improving the efficiency of clinic ...Moderator
-
The threat of antimicrobial resistance is growing globally as the use of higher doses and repeated courses of antibiotics drives more resistant bacteria. Yet innovation in infectious disease has been ...Speakers
-
The bioeconomy—encompassing industries that leverage biological resources, processes, and principles—spans sectors such as biotechnology, agriculture, pharmaceuticals, bioenergy, and synthetic biology ...ModeratorSpeakers
-
The new Unified Patent Court (UPC) system in Europe has been described as a game-changer with respect to patent litigation, particularly when there are infringing activities in both Europe and the Uni ...
-
In a complex and ever-evolving landscape—with shifting regulatory pressures and stakeholder expectations—biotech and pharma companies must continue prioritizing transparency to build trust, maintain a ...
-
The therapeutic use of psychedelics is no longer a pipe dream – they are on the verge of potentially transforming the way we treat brain health disorders. As companies progress psychedelic therapies i ...Speakers
-
In recent years, investors have leaned toward being “risk off” for truly innovative therapies, such as first-in-class or first-in-disease drugs, with a preference for lower-risk drug discovery opportu ...
-
Today's undervalued category is tomorrow's over-crowded sector, yet newcomers are emerging. This panel will examine issues, opportunities, and approaches to dealmaking among an emerging generation of ...
-
Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
.jpg)
.jpg)
3:00 PM
-
For too long, psychiatry has relied solely on clinical observation to prescribe treatments, overlooking the biological differences that impact how patients respond to medication. This trial-and-error ...
-
siRNA, mRNA, pick-your-favorite-RNA, CRISPR, ADCs, PROTACs, molecular glues, precision-meds, CAR-T, epigenetic and allosteric modulators, AI/ML-everything, tissue-selective nanoparticles, AAV delivery ...
-
This panel will showcase the authentic sustainability efforts that pharmaceutical companies in Latin America are conducting, explaining how they have committed to environmental responsibility without ...
-
Cell and gene therapies (CGT) are proving their worth as life-saving treatments, from cancers to rare diseases, but bringing these innovations to the masses will require substantial advances in manufa ...Moderator
-
This session will explore how CEPI (Coalition for Epidemic Preparedness Innovations) and its global partners mobilize during an outbreak, highlighting how strategic partnerships and rapid vaccine deve ...
-
Over the past decade, European biotech has seen remarkable growth, driven by increasing early-stage investments and the creation of promising start-ups. VIB, a leading life sciences research institute ...
-
While the industry is moving forward with the blending of technology and science, the legal landscape is quite different in one of the largest markets: the United States. The Loper Bright ruling this ...Moderator
-
Artificial intelligence (AI) and related technologies offer new avenues of drug discovery productivity never before possible. These innovative methods not only provide significant value to the biophar ...
-
For biotech companies planning an IPO, navigating market dynamics, investor expectations, and regulatory hurdles is critical to success. This session brings together industry leaders to share insights ...ModeratorSpeakers
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.png)
4:15 PM
-
In 1901, the first Nobel Prize was awarded to recognize those who “have conferred the greatest benefit to humankind.” Often the work that goes into winning this prestigious award occurs over decades a ...
-
The rapid advancement of DNA foundation models is transforming our ability to decode complex genomic patterns and regulatory mechanisms. This session will explore the current state of these models, th ...Speakers
-
This session will explore the priority review voucher (PRV) program as proposed in a 2006 paper by Ridley, Grabowski, and Moe and became law in 2007. The PRV allowed the FDA to encourage R&D in neglec ...Speakers
-
This past year has seen many early-stage deals involving platform technologies ranging from AI drug discovery to building blocks for gene therapy products. In this panel, speakers will explore platfor ...ModeratorSpeakers
-
There is much to be said for the humanitarian impulse to expand access to life-saving medicines in resource challenged geographies, but the realities on the ground tell us that the humanitarian impuls ...Moderator
-
The session explores novel technologies and public-private partnerships that can end deaths from influenza in our lifetime. Last flu season saw illnesses, medical visits, hospitalizations, and deaths ...Moderator
-
As biological threats evolve, traditional stockpiling strategies need to adapt to ensure both readiness and flexibility. This session will delve into dual-use models that serve commercial and public h ...
-
As it has touched so many different areas of human activity, so has artificial intelligence (AI) touched biotechnology and, by extension, biotechnology intellectual property. Panelists will discuss th ...Moderator
-
In a recent survey, overall partner ratings by large pharma customers were much higher in comparison to ratings given by smaller biotechs, displaying a potential disparity in how partner organizations ...Speakers
-
As the search for effective treatments for Alzheimer’s disease intensifies, join us for a compelling panel discussion on the next-generation therapies reshaping the landscape of this devastating condi ...
.jpg)
.jpg)
.jpg)
11:00 AM
-
The US life science industry and ecosystem have been an unparalleled engine for transformative medical innovation since the passage of the Bayh-Dole Act in 1980. Since then and through 2022, fueled by ...ModeratorSpeakers
-
“Insanity is doing the same things over and over but expecting different results,” Rita Mae Brown. Most of us would agree. And yet, year after year, we invest over $90 billion in R&D, only to face a s ...ModeratorSpeakers
-
In recent years, public health advocacy has played an increasingly critical role in shaping legislation and policy decisions regarding vaccines. Shifting political landscapes, public opinion, and misi ...Speakers
-
From R&D, regulatory approval pathways to considerations for launching cell and gene therapies, this session is intended to shed a light on European and Middle Eastern (focus on Saudi Arabia and UAE) ...ModeratorSpeakers
-
As the demand for personalized therapies increases, the ability to efficiently produce living medicines at scale is more critical than ever. This session will explore cutting-edge advancements in biom ...
-
Developing innovative diagnostic tests that address unmet clinical needs and improve upon standards of care requires a significant investment of time and resources. Precision medicine companies willin ...
-
How do venture capitalists evaluate early stage life science companies to decide where to place their bets? Learn how high-profile VCs evaluate startups, and what data sets are most important for earl ...
-
Women on social media sites (TikTok) have been speaking out about IUD pain, with some describing the procedure as “the worst pain imaginable” or saying they “almost passed out.” Duke University resear ...
-
Public-private partnerships and supportive state legislative measures aimed at growing biomanufacturing capacity in the United States are providing significant economic on-shoring value, and are essen ...
.jpg)
.jpg)
.jpg)
1:30 PM
-
Whether you're just starting your career or looking to take the next big step, this session will help you navigate the biotech industry. We will begin with an overview of what biotechnology is and its ...
1:45 PM
-
This panel will explore the vital role of patients and their families in driving innovation in rare disease therapies. By sharing personal experiences and expert insights, panelists will highlight how ...Moderator
-
Biotechnology companies are producing remarkable therapies at an unprecedented pace. In the past year, two new gene therapies have come to market for patients suffering from sickle cell disease. Rapid ...Speakers
-
This session will explore how investments and bold bets in accelerated computing, data generation at scale, and model-first strategies are revolutionizing the industry, without ignoring the initial ch ...
-
The rapid advancement of cell therapies has opened new frontiers in regenerative medicine, but it has also highlighted significant regulatory hurdles across global jurisdictions. One of the most press ...
-
R&D is often the most cost-intensive and risky step in a new drug's life cycle yet often dictates the speed and adaptability of the innovation ecosystem. The time and capital required for biotech to t ...Speakers
-
The cancer therapeutics landscape is constantly evolving as breakthroughs across modalities drive toward the shared goal of providing accessible and life-saving treatments to patients. Companies are a ...
-
Representatives from biotech, academia, patient advocacy, and the investor community will have a robust and interactive discussion about next generation therapies to treat blinding eye diseases that a ...
-
This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
-
Join us for an exclusive fireside chat with Feng Zhang, PhD, renowned scientist and core member of the Broad Institute, an Investigator at the McGovern Institute for Brain Research, the James and Patr ...
.jpg)
.jpg)
.jpg)
3:00 PM
-
Initially drafted in January 2023 and finalized in August 2024, the US Food and Drug Administration (FDA) released guidance tied to Project Optimus, titled “Optimizing the Dosage of Human Prescription ...
-
Recent Nobel Prizes in deep learning, structure prediction, microRNA, and mRNA signal that the pharmaceutical industry is entering a new era of innovation, driven by the rapid rise of generative and f ...
-
Originally pioneered as lifesaving treatments for patients with cancer, cell therapies have burst onto the biotech scene as promising, disease-eliminating treatments for autoimmune disorders – a notor ...
-
The legal challenges to the Inflation Reduction Act are now mature. It is critical to assess, at this inflection point, what they have and have not accomplished. As cases move from the District Courts ...
-
The economics of rare-disease research is a consistent obstacle to progress. Although there are more than 10,000 rare diseases that collectively affect over 30 million people in the United States, eac ...
-
Nearly a quarter of adults in the United States report difficulty affording prescription drugs which is often attributed to the drug’s price set by the manufacturer rather than to the patient out-of-p ...
-
This panel will explore the opportunities and hurdles in the dynamic field of advanced biologics manufacturing, where innovative technologies intersect with medical advancements. This domain offers si ...
-
What does it take to create a new medicine? The trajectory from laboratory to your neighborhood chemist rarely runs in a straight line. Eureka moments come few and far between. Drug discoveries demand ...Speakers
.jpg)
.jpg)
.jpg)
.jpg)
4:15 PM
-
According to the most recently available figures, more than 2,000 new oncology clinical trials have begun since 2023, demonstrating the continued need for innovative and effective cancer therapies. Wh ...
-
The commitment to women’s health has been increasing over the past year from the US government and dedicated early-stage seed funds. As this funding is deployed to promote innovation and provide solut ...
-
Intellectual property rights are the bedrock of life-science innovation. But attacks on numerous fronts, from pervasive anti-patent myths to attempts to misuse march-in rights, now threaten to erode t ...
-
Co-discovery and co-development partnerships have become a cornerstone of the biopharma industry. These partnerships can unlock the potential for groundbreaking medicines, yet their scientific complex ...
-
Why are so many drug discoveries still failing to make it out of the lab when the speed of, and competition for, innovation has never been higher? Could solving this challenge lie in the unique relati ...
-
We are witnessing a revolution in rare disease drug development. Traditional models fall short due to small patient populations and limited disease understanding. However, regulatory agencies are now ...
-
Biopharma’s ability to create new drugs has depended, from the start, on our collective knowledge of Earth’s genetic biodiversity. While many existing datasets have sought to describe the world, they ...
-
Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: Four Industry-Academic ModelsA steady and impressive track record of growth in the life sciences industry has kept access to a skilled, diverse workforce at top of mind for life science leaders, even amid occasional retractions. ...Speakers
-
As gene editing and epigenetics evolve, they are not only transforming how we approach complex diseases but also unlocking new possibilities for enhancing longevity, healthspan, and even organ transpl ...
-
Following his fireside chat, join Dr. William Pao for a book signing and meet and greet.
-
As the biotechnology sector continues to evolve and innovate, so does various health regulatory authorities that continue to ensure patient safety and access. In this panel, representatives from vario ...
.jpg)
.jpg)
.jpg)
.jpg)
9:00 AM
-
Biotech startups emerging from universities are at the forefront of innovation, pushing the boundaries of science and medicine. However, translating groundbreaking research into viable commercial prod ...ModeratorSpeakers
-
As AI becomes integral to healthcare, ensuring transparency and trust through regulatory compliance is critical. Multi-agent systems, where different AI agents specialize in distinct tasks, are gainin ...Moderator
-
Back by popular demand! Whether in-licensing, out-licensing, or fundraising, shaping your company's story in just 15 slides is crucial. Learn two trademarked methodologies, The LHS Immersion Process a ...
-
The Human Genome Project led to an explosion of knowledge about the genetic roots of disease. Now leaders in genetic medicine technologies, including RNAi therapeutics and CRISPR gene editing, are har ...Speakers
-
Biotech is entering a new era of mega blockbusters - drugs with peak sales potential exceeding $10 billion. Drug developers are increasingly focusing on novel therapies that can reach the largest poss ...
-
The tremendous success of GLP-1/GIP receptor agonists has ushered in a rapid paradigm shift in how we consider and treat chronic metabolic diseases, like obesity and associated comorbidities. These th ...
-
Join us for a dynamic panel discussion on Health Equity in Biotech. This session will explore how founders and business development professionals can drive innovation while tackling some of the world’ ...
-
While CAR-T therapies have revolutionized cancer treatment, access remains largely confined to major academic medical centers, limiting treatment availability for most eligible patients. Expanding del ...
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
10:15 AM
-
This session will discuss why, contrary to conventional wisdom, the need for co-pay and premium assistance, in this complicated environment, is likely to increase, not decrease, under the IRA. Panelis ...
-
Countless preclinical- and clinical-stage drugs remain shelved, not for scientific reasons or because they lack demonstrated potential to help patients, but rather because of strategic, organizational ...
-
A new class of conditionally active biologics that is safer and less toxic than existing therapies is emerging. These drugs have the potential to overcome shortcomings of current state-of-the-art ther ...Speakers
-
Emerging modalities are driving the future of the biopharma industry, and pharmaceutical companies are increasingly turning to external sources for these innovations. This panel brings together speake ...
-
The industry is still grappling with GenAI while quantum is lurking around the corner. There are already companies and countries experimenting with quantum. From a business perspective, the ways that ...ModeratorSpeakers
-
New Approach Methodologies (NAMs) are at the forefront of transforming how biomedical research translates into real-world treatments, enabling faster and more precise drug development by, in some case ...Speakers
-
CAR-T and other advanced therapies hold transformative, and even curative potential, however reimbursement bottlenecks are preventing widespread access. Payer hesitation, regulatory complexity, and ot ...
-
The Rare Disease Innovation Hub, established by the FDA in 2024, serves as a pivotal point of collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Eval ...
.jpg)
1:15 PM
-
The 35th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotechnology industry’s standing within a quickly evolving transaction and financing envi ...Speakers
-
Establishing university-industry partnerships enables the realization of ideas and discoveries to become actual products and services that benefit the public. These partnerships present a variety of o ...Speakers
-
Hear a diverse panel of small investors (angels and small VCs) from around the world discuss the role of smaller investors in the lifecycle of biotechnology startup companies – both in the US and over ...
-
Recent data reveals that less than 10% of CEOs in the biopharma industry are women, while female representation in leadership teams stands at 25%. However, the momentum for change is undeniable. A gro ...Moderator
-
Conducting multi-national clinical trials for rare diseases poses ethical and logistical challenges, particularly in ensuring equitable patient access and sustainable commercialization plans. This pan ...Moderator
-
Integrating real-world evidence (RWE) strategies during drug development and commercialization is critical to maximizing shareholder and stakeholder value. Biopharma executives need to know how to lev ...
-
In vivo CAR (Chimeric Antigen Receptor) therapies are poised to revolutionize immunotherapy by moving beyond the limitations of traditional ex vivo approaches. These therapies involve programming immu ...Speakers
-
Biotech goes beyond science - although the building blocks of our industry are made up of groundbreaking approaches that start in the lab, the goal is that they end in one place - impacting patients. ...Speakers
.jpg)
.jpg)
.jpg)
1:45 PM
-
This interactive session is designed to provide students with the guidance and connections needed to navigate entry into the biotech industry. Panelists will share their personal career journeys and i ...
2:30 PM
-
Won an SBIR/STTR grant from the NIH for your biomedical innovation? A new paradigm for inter-agency, industry, and venture capital collaboration is here to help commercialize it! Startups are 50% more ...Moderator
-
This session will delve into the intricate landscape of the US legal and regulatory framework governing the use of artificial intelligence (AI) in pharmaceutical product development. As AI continues t ...
-
Rare disease clinical trials face unique challenges, including small patient populations, high variability in disease presentation, and logistical complexities. This panel will explore innovative stra ...Moderator
-
With the development of RNA therapeutics advancing at an unprecedented pace, the healthcare and pharmaceutical industry is entering an “RNAissance” era. RNA, a molecule that was viewed as a transient ...
-
Computational methods including AI/machine learning have the potential to be transformational in biopharma by accelerating and enhancing many aspects of drug discovery to bring better drug candidates ...Speakers
-
Whether setting a course or changing strategies in today's biopharma landscape, information overload, quickly obsolete insight, and stakeholder misalignment are industry-wide challenges. As an emergin ...
-
Since 2008, Massachusetts has made significant financial, policy, and people investments in the life sciences, including building a broad-based effort to expand pathways to produce diverse talent to d ...ModeratorSpeakers
-
While huge advances have been made in ensuring optimal patient care in oncology where diagnostic testing is required prior to initiation of therapy (i.e. precision medicine), we continue to see practi ...Speakers
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
9:00 AM
-
Currently, the biotech M&A market is subject to a confluence of unique historic forces, both promoting and opposing M&A. Some of these forces include unprecedent M&A demand from big pharma due to the ...Moderator
-
The Accelerated Approval Program has been the focus of many recent conversations questioning the impact and value of the pathway for patients. Drugs approved via this pathway have become the latest vi ...Speakers
-
The global immunology market is projected to nearly double by 2032, expanding from $250 billion in 2023. Immunology and Inflammation (I&I) has now emerged as a top investment priority in biopharma, su ...
-
In recent years, "patient-centric"has emerged as a buzzword in the healthcare world. However, the reality is that our industry has often overlooked the patient voice, which has, at times, impeded the ...
-
This session will delve into how preclinical human data, derived from innovative methodologies such as organ-on-a-chip technology, lab-grown tissues, and advanced imaging techniques, can provide inval ...Moderator
-
An increasing number of cell and gene therapies hold significant promise, but challenges remain in bringing these therapies to patients. These include regulatory, manufacturing and clinical trial chal ...
.jpg)
.jpg)
10:15 AM
-
When innovating toward solutions for the world's greatest health challenges, such as matters of health security, global preparedness, and life-saving health solutions more broadly, time is of the esse ...
-
How can obesity treatments move beyond GLP-1 drugs to offer long-term, patient-friendly solutions? Obesity management is at a pivotal phase, with new opportunities emerging to deliver sustainable weig ...
-
Immunology is entering a new era, presenting unique investment prospects as therapeutic innovations emerge and investors are eager to participate in this attractive field. Next generation I&I therapie ...
-
As the pharmaceutical industry increasingly embraces AI in drug discovery, a pressing question emerges: can AI go beyond merely delivering faster and cheaper drugs? Join our expert panel of C-level ex ...
-
The Inflation Reduction Act (IRA) has caused strong disruption to innovation in drug development, and this impact is falling heaviest on oncology and neuroscience. Cancer drug development has been rem ...Moderator
-
The recent landmark success of gene-edited porcine kidney transplants into human recipients marks a turning point in the future of organ transplantation. With genetic engineering enabling immune-compa ...
.jpg)
.jpeg.jpg)
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}